FAQs アーカイブ - Page 2 of 7

Q: How does the joint research forum among medical professionals function?

The joint research forum among medical professionals serves as a platform for sharing knowledge, developing joint research projects, and exchanging information on the latest medical practices. It includes research presentations, workshops, and discussion sessions, where participants share insights on the cutting edge of diabetes treatment. This enables medical professionals to develop treatments suitable for the local medical environment and improve the quality of patient care.

Q: How is the medical need for diabetes treatment evaluated in Palau?

The medical need for diabetes treatment in Palau is assessed through regular medical surveys and information gathering in the region. This includes data on the incidence of diabetes, frequency of complications, and the capacity of local medical facilities. Understanding the needs and concerns of patients and families through community engagement is also crucial. This information is vital for designing and improving treatment programs.

Q: What are the specialties of doctors and nurses dispatched to the clinic at Sheraton Palau?

The doctors and nurses dispatched to the clinic at Sheraton Palau specialize mainly in diabetes and its complications. This includes specialists in endocrinology, diabetology, general internal medicine, and emergency medicine. They focus on managing diabetes, preventing and treating complications, and providing educational programs to improve the quality of life for patients and meet local medical needs.

Q: What are the current challenges in treating diabetes in pets?

Currently, the treatment of diabetes in pets relies mainly on insulin injections, which are challenging for pet owners to manage daily and can be stressful for the pets. In particular, the frequency and amount of insulin injections need to be precisely managed, which is a significant burden for pet owners. The new drug aims to provide a simpler and more effective treatment method, thereby improving the quality of life for both pets and their owners.

Q: Will the new drug be administered orally or via intravenous injection?

Both methods are currently considered feasible for development.

Q: How is the safety evaluation of the new drug conducted?

The safety evaluation of the new drug is conducted through clinical trials involving a wide range of animal species. This includes observing any side effects from short-term and long-term administration of the drug. Particular attention is paid to chronic health impacts and the drug's effects on specific health conditions. The impact of the drug on the physiological and behavioral characteristics of pets is also thoroughly evaluated. The results of the safety evaluation are submitted to regulatory authorities before the drug's market launch and are a critical criterion for approval. Safety evaluation is essential to ensure the health and safety of both pets and owners.

Q: What are the main challenges in developing new drugs for pets?

The primary challenge in developing new drugs for pets is confirming their safety and effectiveness across different species and sizes of pets. It's necessary to develop treatments optimized for each species, taking into account their physiological characteristics and metabolic differences. Additionally, developing drugs suitable for the specific health conditions and dietary habits of pets is required. This involves extensive clinical trials for major pet species like dogs and cats. Also, developing administration methods that are easy for owners and less stressful for pets is crucial.

Q: What are the current challenges in treating diabetes in pets?

Treatment of diabetes in pets mainly relies on insulin injections. However, this treatment requires complex daily management, posing a significant burden for pet owners. In particular, managing the correct amount and frequency of insulin is difficult for owners, and incorrect management can pose serious health risks to pets. Also, insulin injections can be stressful for pets, potentially reducing the effectiveness of the treatment. The new drug aims to address these challenges, providing a simpler and more effective treatment method.

Q: What is the mechanism of action of the new drug?

The drug normalizes mutated hematopoietic stem cells, which are the cause of diabetes. This approach addresses the fundamental cause of diabetes and its complications. Not only does it reduce the frequency of insulin injections traditionally required, but it also potentially eliminates the need for them entirely. This is expected to significantly improve the daily quality of life for pets.

FAQs

KIYAN Group and Collaborating Research Institutions

KIYAN PHARMA Co., Ltd.

KIYAN MEDICAL Co., Ltd.

Biozipcode, Inc.

Shiga University of Medical Science, Dep. of Regenerative Medicine

Biozipcode, Inc.

Learn More About Us

Contact Us

Languages